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Abstract
The limited availability of biological samples from patients
testing positive for SARS-CoV-2 for future research was
quickly identified at the onset of the COVID-19 pandemic.
In response to this need, a COVID-19 biobank was initiated by the University of Louisville Division of Infectious Diseases, Center of Excellence for Research in Infectious Diseases (CERID). The COVID-19 biobank contains waste samples obtained from patients hospitalized with COVID-19 in

any of the nine Louisville, Kentucky, area hospitals during the
timeframe of April 13 to September 20, 2020. The COVID19 biobank stores approximately 1,623 waste samples with
2,127 aliquots for distribution. All samples are linked to clinical data. The methods described in this paper are intended
for use as a guide for other research institutions interested in
developing a COVID-19 biobank.

Introduction

tiated. The development of the COVID-19 biobank included creating new methods to identify patients hospitalized with COVID-19, obtain, store, release, and
inventory waste specimens and associate these specimens with clinical data.[3] For this to occur, the new
biobank required development of additional organizational capacity that could provide a foundation for anticipated growth and increased interaction with clinicians and basic scientists. The following information
outlines the implementation approach for the CERID
COVID-19 Biobank.

The ability of the novel SARS-CoV-2 virus to produce a
broad spectrum of clinical presentations in patients has
prompted significant research interest across multiple
healthcare disciplines. In March 2020, the University
of Louisville Division of Infectious Diseases Center of
Excellence for Research in Infectious Diseases (CERID)
initiated a COVID-19 surveillance program enabling
testing of patients seen in any of the nine Louisville
and two southern Indiana area hospitals. This surveillance work resulted in the testing of more than 6000
respiratory samples for SARS-CoV-2 of which 1,026
tested positive for the virus.[1] The development of the
surveillance process was used as a guide to develop
the COVID-19 biobank process (IRB# 050556).[2] These
positive specimens were retained in the existing CERID
Biobank focused on emerging pathogens. This original
biobank was implemented in 2005 focusing on discovery of new and emerging pathogens and biomarkers.
This biobank currently houses more than 70,000 human
samples all linked to clinical data maintained in a webbased secure REDCap database.[4] To enable rapid access to specimen by multiple disciplines interested in
this novel virus, a new branch of the biobank was iniULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/71

Objectives
The objectives of this program review are to describe
the steps involved in initiating a COVID-19 biobank
process including: 1) methods to identify hospitalized
patients with a COVID-19 positive test result and/or
ground glass opacities on chest CT; 2) processes for obtaining waste specimen from patients identified with
COVID-19; 3) logistical procedures to catalogue and
label specimen for storage, location, and retrieval; 4)
database development and clinical data entry; 5) quality assurance review; and 6) description of organizational capacity necessary to successfully operate and
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manage a COVID-19 biobank.
Methodology
The University of Louisville Division of Infectious Diseases implemented a biobank of specimen in 2005 in
response to the growing concerns with multidrug resistance and emerging pathogens. The focus of that
biobank has been the capture of specimen with a link
to clinical data of the patient in an effort to support research in both the clinical care and basic sciences. That
current biobank contains more 70,000-patient specimen
including blood, urine, tissue and respiratory samples, all linked to clinical data maintained and managed using HIPAA-compliant electronic capture data
tools hosted at the University of Louisville. REDCap (Research Electronic Data Capture) is a secure,
web-based software platform designed to support research studies.[4] The process of expanding the existing biobank and implementing a new component focusing on COVID-19 branch required development of a
comprehensive process utilizing an array of resources.
The following steps were undertaken by the CERID
team members in development of this new biobank
component: 1) development of a new database and
corresponding data dictionary focusing on clinical patient data corresponding to the collected waste samples; 2) creation of an identification coding process for
each sample; 3) procedures for specimen collection and
transportation from each of the nine Louisville area
hospitals to the biobank site; 4) development of a data
collection manual and data entry process; 5) systems
for processing samples for placement in the biobank;
6) procedures for cataloging the samples for location
and retrieval; 7) procedures for sample identification
and labeling; 8) procedures for storage of samples in
the biobank; 9) development of a process for researcher
and industry access to biobank sample menu and request process; and 10) development and implementation of quality assurance procedures and metrics.
Specimen database development
Members of the CERID Biostatistics and Data Management Units created the COVID-19 REDCap database
to support the biobank objectives of maintaining, analyzing, and sharing COVID-19 patient samples and related clinical data with the research community. This
required that the database development team have the
ability to provide basic patient information outlined in
the Institutional Review Board (IRB) approval. Data
elements included patient demographics, history and
physical examination, laboratory and radiologic findings, medication history, and clinical course of illness.
Development of the database required parallel development of a data dictionary that described each data
element along with acceptable ranges and rules for
data entry. For example, formats for date of birth,
hospital codes, and general laboratory result ranges
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were included and drop-down boxes development as a
means of addressing preventable data entry error. The
database was then pilot tested using paper data collection tools that assisted with rapid development without
wasted effort correcting or changing major database
approaches or elements. The end result is a biobank
database able to provide an efficient mechanism to
grow, maintain and monitor the SARS-CoV-2 sample
inventory, and track and make available samples to researchers worldwide.
Creation of the sample identification code
To differentiate the samples entering the COVID-19
biobank, a unique subject identification code and sample labels were created. The abbreviation of “COD”
was used to designate the COVID-19 project. Each
participating hospital was assigned a hospital code to
identify the origination of the sample and the clinical
data. Each sample was also provided a sample number that would allow placement of sample aliquots in
similar locations for ease in retrieval. An example of
the identification code for these samples is “COD-010001”. Using this alphanumerical system allowed for
additional hospital sites to be added and enabled up to
one thousand samples from each hospital to be stored
in the COVID-19 biobank. The Marketing Unit then
created a prototype of the sticker using that specimen
labeling convention for consistency in appearance.
Specimen collection and transport from hospitals to the
biobank
The initial IRB approval allowed for collection of waste
samples from hospitalized patients diagnosed with
COVID-19. Individual procedures for sample collection were developed at each hospital recognizing that
procedures in facility laboratories reflected their local practices. Initial meetings were held with laboratory managers to outline the goals of the biobank,
processes for identify patients with COVID-19, types
of waste specimen requested, procedures for identifying those samples, and a location for specimen to be
held awaiting pickup by CERID researchers. Specimen
were transported by CERID researchers to the biobank
using temperature-controlled transport containers and
immediately placed in a designated refrigerator upon
arrival to the biobank.
Procedures varied widely among participating hospital laboratories. For example, one hospital chose to
have the Infection Preventionist provide a list of patient names and medical record numbers (MRNs) so
they could develop lists to provide to the hospital laboratory. Another hospital assigned that responsibility
to one of the infectious diseases physicians, while another authorized access to screening reports via their
electronic medical record system. A major goal of this
aspect of work involved identification of a process that
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Figure 2. Retreiving waste samples from UofL Hospital Laboratory.
Figure 1. ID label and sample type.

was sustainable for both the hospital and researcher
while also minimizing disruption to hospital personnel
work and workflow.
After identifying new patients that met the biobank inclusion criteria, a report was generated that included
patient name, date of birth and medical record numbers (MRN). The list was cumulative with patients being removed from the list after discharge. This enabled a process to add waste specimen and clinical
data throughout the course of hospitalization. Waste
samples for the COVID-19 biobank include whole
blood, serum, plasma, urine, stool, nasopharyngeal
swabs, oropharyngeal swabs, sputum, bronchoalveolar lavage, pleural fluid, cerebrospinal fluid and tissue.
Each waste sample was already labeled with patient
information according to the individual hospital procedures (Figure 1). Laboratory personnel at the individual hospital placed patient samples into a biohazard
bag then placed in a designated refrigerator in the laboratory area. CERID team had placed a basket clearly
labelled as COD into the designated refrigerator for
CERID researchers to pick up (Figure 2).
Upon arrival to the biobank, a color-coded label was
applied with the unique identifier for each hospital
and the sequential specimen number as previously described. Each hospital had been designated a specific
color. When the samples were logged in to the biobank,
the hospital-specific forms were retrieved from premade color specific folders and the corresponding
Biobank Screening Log form and a set of COVID-19
Subject ID regular and Cryogenic labels (Figure 3) were
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used to document receipt of the specimen and provide
labels for the tubes. The COVID-19 Biobank Screening
Log was completed with patient details (name, date
of birth, medical record number). The waste sample
details (type, date of collection, accession number assigned by the providing hospital) were then entered
onto this form. A final check was done to ensure all
samples collected were documented on the screening
log. A subject COD ID label was placed on the sticker
on the front of the colored file folder, on the COVID19 Biobank Screening Log form and on the biohazard
bag. Cryogenic labels were placed inside the biohazard bag. At this point, all information documented on
the COVID-19 Biobank Screening Log was handwritten
and in ink.
The biohazard bag containing the waste samples and
the Cryogenic labels were then placed in a designated
labeled basket in the biobank refrigerator for laboratory personnel to process (Figure 4). For patients that
were previously entered into REDCap, the COVID-19
Biobank Screening Log was updated with the new sample details (type of sample, date of collection, accession
number). New Cryogenic labels with the same Subject
ID of the patient were printed and placed in the biohazard bag. The CERID researcher was then responsible
for data entry for all specimen received and placement
of the file folder(s) in a designated area for quality team
review.
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Figure 3. UofL Hospital folder, labels, and biobank screening log.

Figure 4. Designated basket for COVID-19 waste samples.
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Figure 5. Initial data entry form.

Figure 6. Biobank information.
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REDCap data entry

10. Clinical course during hospitalization

Initial data entry into REDCap occurred at the biobank
when the implementation team arrived to drop off samples obtained from the hospitals for processing. There
were two sections in the REDCap database to be completed at the biobank; 1) initial patient data, and 2)
Biobank Information Sections (Figure 5 and Figure 6).
Completing these sections at the biobank provided the
laboratory personnel all required information necessary to promptly process the samples for storage. The
information in these two sections contain information
regarding the who, what, when, and where regarding
both the patient and sample history. Beyond allowing
the CERID team to begin to build a data history for
each sample, this process generated a REDCap unique
data identification code. This code is an alphanumeric
marker for each sample that allowed researchers to deidentify samples, track samples for inventory purposes,
and for the team to securely attach clinical data to the
sample record in the future. After the Initial Data and
Biobank sections of the database were completed, the
samples were placed in a refrigerator for the laboratory
personnel to process.

11. Cardiovascular events

Standard data elements for each patient entered into
REDCap included the following data points:

The processing of the COVID-19 sample for storage in
the biobank occurred in a biosafety level 2 laboratory
(BSL-2) in a biosafety cabinet (BSC). This bio-level certification provided the required safeguards when working with bio-specimen agents associated with human
diseases. These sample processing procedures requires
the participation of two trained laboratory technicians
to complete the work safely and accurately. The processing team consists of two laboratory technicians, one
who completed the bio-processing work under the BSC
and a second technician who worked in parallel to handle the data collection and inventory documentation
of the process. This lab work required the following
supplies; a single channel repeater pipette, disposable
transfer pipettes and 1mL pipette, repeater pipette tip,
micro pipette tips, 1.7 ml CRYO tubes, Falcon tubes,
PIPES buffer, preprinted CRYO stickers with subject
ID, CRYO boxes/ freezer storage boxes for sample storage. When laboratory technicians processed the biological samples in the BSC, they follow specific laboratory
safety guidelines and protocols based on the type of biological sample type being processed at the time. These
specific process protocols are described in the following
paragraphs.

1.

Cycle threshold (Ct) value from PCR assay for
SARS-CoV-2

2.

Hospitalization date and admitting diagnosis

3.

Patient health history
•

Signs & symptoms within 24 hours from onset
of symptoms

•

Past social history

•

Psychiatric history

•

Past medical history

•

History of Pulmonary and Respiratory Infections/Disease

•

HIV history

•

Risk factors for cardiovascular events

•

Chronically used medications prior to onset of
symptoms

12. Clinical outcomes
13. Notes (for comments)
Processing of the samples for placement in biobank
The processing of waste samples for storage in the
biobank began immediately after sample arrival, labeling and specimen data entry. The biobank laboratory staff completed the following steps: a) created a
daily paper biobank inventory log used for tracking
all received sample types, b) transferred this information into the biobank’s electronic Microsoft Excel file, c)
applied COD ID label(s) to the designated Eppendorf
CRYO tube(s) and documented the sample type (e.g.
blood, plasma, serum, urine, nasopharyngeal swabs),
volume and location (e.g., freezer, shelf, drawer) of the
sample(s) into REDCap database. This information was
used to easily identify sample type and location for future retrieval.

4.

Maternity-specific data

Blood and respiratory samples

5.

Physical examination and laboratory findings

6.

ICU course and ICU lab data

7.

Radiological and CT findings

8.

Microbiological studies

9.

Management and therapy of COVID-19

Two laboratory technicians were required to process
daily samples. One laboratory technician began the
process by donning the appropriate PPE (gown, gloves,
and facemask) prior to beginning to work with the
COVID-19 biospecimen in the BSC. When processing
respiratory and blood samples laboratory personnel
started by opening the sample biohazard bag and placing the hospitals collection tube(s) in a sample tube

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/71

6

ULJRI

Implementation of the University of Louisville COVID-19 Biobank

Figure 7. Aliquoting blood into CRYO tube.

Figure 8. Aliquoting plasma into CRYO tube.

rack. Next, the technician mixed the sample in the first
collection tube to ensure the uniformity of the specimen
in the tube prior to aliquoting it. The technician then
opened the first collection tube and began to pipette
the sample from the collection tube into a minus eighty
degree rated 1.7 mL CRYO tubes(s) (Figure 7). When
aliquoting the sample, technician pipetted an equal volume of 0.5 mL into each CRYO tube and securely tightened the cap on each CRYO tube and places the tube
into a rack. This transfer process continued until the
entire collection tube’s volume has been pipetted into
CRYO tube(s). The technician continued this process
until all the respiratory and blood sample collection
tube(s) from all subjects of interest in this study for the
current day had been transferred into the CRYO tubes
and racked.

into the CRYO tubes and placed on completed rack.

Urine samples
Laboratory technician donned the required PPE (gown,
gloves, and facemask) prior to beginning the process.
Laboratory technician opened the sample biohazard
bag in the BSC and placed the hospitals collection cup
next to the sample tube rack. The personnel then added
0.250ml of PIPES buffer to a new Falcon tube location
on the tube rack in the hood. Next, the technician
opened the urine sample and uses a transfer pipette to
add 4.75 mL of the urine sample to the buffer in the Falcon tube. The Falcon tube was then sealed, and the tube
was continuously inverted (a minimum of ten times)
until it is well mixed. Once the tube is mixed, the urine
sample was aliquoted into 0.5 mL in each CRYO rated
1.7 mL Eppendorf tubes and capped on the completed
tube rack. This urine sample transfer process to the
CRYO tubes continued until the Falcon tub is empty.
The technician continued this process until all the urine
collections from the current day had been transferred
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Stool samples
In processing the COVID-19 stool sample(s) once the
PPE was donned, laboratory technicians began by retrieving the stool sample from the biohazard bag and
inspected the sample to identify if any Cary Blair
(C.Blair) solution would be required to increase the viscosity of the sample being transferred from the collection cup into the CRYO tube(s). If the sample contained
the needed fluidity, then the sample was transferred directly into the CRYO tube(s). If the sample was solid in
consistency, then laboratory technician would pipette
a small volume of C.Blair solution into the collection
cup and mix the sample to loosen it to a level where
transfer is achievable. Once the required volume had
been transferred the CRYO tube was securely closed
and placed on completed rack. The technician continues this process until all the stool collection samples
from the current delivery had been transferred into the
CRYO tubes and placed on completed rack.
Plasma samples
After donning proper PPE, laboratory technician begins the process by opening the biohazard bag and confirming the waste sample as plasma. This identification
is done by inspecting the label on the collection tube
for plasma designation, referring to the laminated informational guide for identifying sample types based
on the lid color of the collection tube or inspecting the
contents of the tube to confirm if there is a distinctly
separated blood clot resting in the bottom of the tube.
The laboratory personnel then aliquoted 0.5 mL of the
plasma sample off the supernatant layer and pipettes it
into a CRYO tube (Figure 8). Once the sample trans-
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Figure 10. CRYO tubes placed in storage box.
Figure 9. Paper log containing: subject ID, date received, volume
(mL), biobank box location #, tube location, drawer/rack/shelf/freezer,
comments.

ferred the technician then capped and placed the tube
on the completed tube rack. The technician continued this process until all the plasma collection tubes
from the current day had been transferred into the CRYOtubes and placed on completed rack.
Serum samples
Laboratory technicians began the process by retrieving
the sample tube from the biohazard bag and confirming the waste sample as serum. This identification was
done by inspecting the label on the collection tube for
a clear serum sample designation, or referring to the
laminated informational guide for identifying sample
types based on the lid color of the sample collection
tube, or inspecting the contents of the tube to confirm
if there is a distinctly separated serum layer in the tube.
The technician then aliquoted 0.5 mL of the serum sample off the supernatant layer of the solution in the tube
while making sure not to collect any volume from the
WBC layer in the collection tube. Once collected the
technician pipetted it into a CRYO tube then capped
and placed on the completed tube rack. The technician continued this process until all the serum collection tubes from the current day had been transferred
into the CRYO tubes and placed on completed rack.

cessing is completed. This highlights one of the most
important steps of the data collection process as it allows the COVID-19 sample to be tracked over its storage life (five-year maximum) in the biobank in addition to be the source document for all future data entry related to the samples. This data collection process
was performed by two laboratory technicians to ensure
quality assured data accuracy and safe laboratory techniques when working with COVID-19 samples.
While laboratory personnel continue to work in the
BSC, the second laboratory technician works in parallel to document and produce the biobank inventory
log. During this process one technician is designated
to work under BSC, transcribing the collection samples
one at a time and verbally documenting and verifying the requested sample log information to the other
laboratory technician. As the technician obtained the
data, they record it onto the biobank inventory paper
log (Figure 9). When all information is retrieved off of
the collection sample tubes the samples are stored in
freezer boxes (Figure 10). The technician then moved
forward with the data management work by beginning
to complete the log and then transferring the sample
data to the electronic version of the log.
Transfer of the sample log data

Cataloging the samples during laboratory processing
After laboratory personnel have completed the initial
COVID-19 sample transferring processing steps; the
second step of the process was creating the biobank inventory log paper (Figure 8). This document contains
subject identifiers, sample collection data, number of
aliquots, volume aliquoted, sample type and storage locations that the tube will occupy after the biobank pro-

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/71

Once the paper copy of the biobank inventory log contained the data from the hospital collection tubes the
focus of the technician was to transfer the data from
the inventory log sheet to the laboratory data excel file
(Figure 11). The data are transferred to the electronic
version by technicians for two purposes. Maintaining
this log electronically on an encrypted university machine adds another layer of security for sensitive data
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Figure 11. Biobank Excel inventory log.

and it allows multiple teams at various locations in the
division to access the data as needed. This is important as specific sensitive biobank data may be required
by personnel throughout CERID for tasks such as; data
entry into the REDCap data base, quality checks for all
steps of the data management process, biobank inventory inquiries, and miscellaneous research tasks.
Application of the sample identification labels
As the transfer of the daily sample delivery into
the CRYO tubes was completed, the two technicians
turned their attention to the last process step prior to
the samples being stored in the biobank. This step involved the application of the CRYO tube identification
labels to the CRYO tubes and the recording of the subject ID number from the CRYO label onto the laboratory logs under the correct research sample. In this process technician one removes the CRYO label from the
biohazard bag and matches it to the correct CRYOtube
on the completed sample rack and applies it, so the
all digits are visible. Laboratory technician then communicates the unique sample ID to technician two to
record it on both the hard copy log and in the electronic
version of the log. The process of applying labels and
recording sample ID’s continues until all samples had
been labeled and recorded.
Storage of samples in the biobank
After the sample processing has been completed the
CRYO tubes are ready to be placed in the biobank for
storage. Storage of the samples must align with the
daily biobank location within the CRYO box in which
it will be stored. Each box has space dividers, enabling
the box to hold 81 CRYO tubes. Thus, each sample
will then have a spot designated between 1-81. Each
box itself will also be numbered due to the frequency,
volume, and complexity of samples for the study and
its associated subjects. The box is then given a permanent location within a -80 degrees C Freezer. Due to the
number of specimens housed in the UL Biobank, multiple freezers are needed, and each freezer is numbered.
Within each freezer is a numbered shelf (1-4), rack (1-5),
drawer (A-D), and position (A1-D4) (Figure 12). This
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detailed arrangement makes for a comprehensive and
easily locatable biobank of biological specimens, making it efficient, convenient, and quality assured.
Biobank sample request process development
The CERID leadership’s main objective of creating a
COVID-19 biobank was to build an abundant repository of various samples from patients testing positive
for SARS-CoV-2 and reducing any barriers to obtaining samples in support of research. To achieve this goal
CERID leadership and the laboratory unit agreed that
anyone interested in biobank samples should simply
contact the CERID director to make the request. The
CERID director would then facilitate the transfer of the
sample(s). The biobank team will expedite shipment
of the requested samples and update the inventory of
available aliquots.
Quality measures
The CERID Quality Assurance Unit is responsible for
ensuring research accuracy at every stage of the process. CERID leadership understood that the work of
identifying and correcting the errors that arose from
such an intensive process was critical in maintaining
the integrity of the biobank and in providing quality
data to future researchers. This process was accomplished by assigning specific researchers from the quality unit to conduct a systematic evaluation of the process. These personnel were trained in each step of the
process and helped in the construction of the quality
metrics. These metrics and the quality steps utilized in
the process can be seen in the following table (Table 1).

Discussion
The novel SARS-CoV-2 virus rapidly spread across the
globe causing increased morbidity and mortality. During a pandemic, recognition of acquiring waste samples from persons infected with a new disease is essential for continued research projects. Waste samples are
necessary for understanding the viral properties, mutations, development of treatment modalities, development of successful medication regimens, and vaccine
9
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Table 1. Quality metrics for development of the COVID-19 biobank.

Quality Metrics for the development of a COVID-19 biobank
Process Steps

Quality Metric

1) Specimen database development and maintenance.

HIPAA and IRB compliant.
Restricted gatekeeping ability for section entry based on the
need and task related to specific team members.
Realtime structure editing based on continuous program evaluation

2) Production of the sample identification code.

Unique deidentified alpha numeric code containing study name,
sample collection location, and subject

3) Specimen collection and transport from hospitals to the
laboratory.

Packaging sample appropriately for transport CRYO labels accompanying each specimen
Specimen biohazard bag labelled
Specimen label legible

4) Data entry and generation of REDCap ID number.

Mandatory data completion fields to prevent missing data
Utilization of check boxes and drop-down choices to prevent text
data errors
Certification of all demographic information
Specimen type verified verses lab record
Identity of data entry personnel via history feature

5) Processing of the samples for placement in biobank.

Mandatory PPE for staff in contact with positive samples.

6) Cataloging the samples during laboratory processing.
7) Application of the sample identification labels.

Protocol requiring two lab members (crosscheck) working together to prevent error in all lab steps of the process

8) Storage of samples in the biobank.
9) Biobank sample request process development.
10) Quality measures.
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Figure 12. Freezer placement.

development to name a few. The hope is that the information provided in this methodologies article provides guidance for others considering creating a new

or adding to an existing biobank to provide researchers
specimens to help prevent morbidity and mortality in
this and other pandemics in the future.
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